Last reviewed · How we verify

NCT03576456

Sedative Premedication in Coronary Angiography

Status unknown NA Last updated 12 October 2018
What this trial tests

NA trial testing Alprazolam 0.5 mg in Coronary Angiography in 264 participants. Status unknown.

Timeline
1 January 2019
Primary endpoint
1 January 2020
1 August 2020

Quick facts

Lead sponsorUniversitair Ziekenhuis Brussel
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment264
Start date1 January 2019
Primary completion1 January 2020
Estimated completion1 August 2020
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universitair Ziekenhuis Brussel — full company profile →

Who can join

Adults 18 to 99, any sex, with Coronary Angiography or Sedative Premedication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of the possible positive effect of sedative premedication prior to coronary angiography in regards to pain and anxiety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Alprazolam 0.5 mg

Trials testing the same drug.

Other recruiting trials for Coronary Angiography

Currently open trials in the same condition.

Other Universitair Ziekenhuis Brussel trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03576456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing